DONQ52 for Symptomatic Celiac Disease on Gluten-free Diet

This study is focused on finding out how effective a new drug called DONQ52 is for people with celiac disease, particularly those who still have intestinal damage and symptoms even though they are trying to follow a strict gluten-free diet. The aim is to see if this drug can help repair damage in the small intestine and reduce the symptoms caused by gluten exposure. This is important because many people with celiac disease continue to experience health issues despite avoiding gluten, and this study could lead to better treatments and improved quality of life for them. Participants in the study will receive either the drug DONQ52 or a placebo, which is a substance with no active medication, to compare the effects. The treatment is administered to see if it can improve the structure of the small intestine, specifically measuring changes in a ratio that indicates the health of the intestinal lining. The study will assess whether the drug helps in restoring the normal structure of the intestine and reducing symptoms. Researchers will use a method to analyze changes in this ratio over time, with a focus on whether the drug leads to improvements compared to the placebo.